Consent-governed genomic insight
MyDNABank helps biotech and precision medicine teams discover, request and analyse consented genomic cohorts through a standards-based access model. Raw participant data is not downloaded or handed over.
Why current access models break
Biotech and precision medicine programmes need high-quality genomic and phenotype data. Current access models are often fragmented, slow, inconsistent, and difficult to govern.
Useful cohorts sit across institutions, labs, biobanks, and consumer platforms.
Commercial research permissions need to be clear, traceable, and enforceable.
Teams often cannot assess cohort availability before expensive access work begins.
Precision medicine context
Whole genome sequencing alone is not enough. Precision medicine depends on linking genomic data with phenotype, lifestyle, outcomes, and longitudinal health signals.
Disease area, symptoms, family history, medication response, and participant-reported context.
Future health updates, recontact pathways, and evolving participant data over time.
Nutrition, fitness, environmental, and behavioural signals that improve cohort understanding.
Commercial use cases
MyDNABank supports approved commercial research where cohort discovery, consent, analysis, and outputs need strong governance.
Test whether genetic variation supports a target in consented cohorts.
Identify genomic and phenotype patterns linked to disease subtypes or response groups.
Find genetically stratified populations before recruitment.
Governed access
MyDNABank is designed around cohort discovery, consent-aware access, controlled analysis, and approved research outputs.
Search structured genomic and phenotype profiles to evaluate cohort feasibility.
Confirm whether the intended commercial or research use aligns with participant consent scope.
Approved workflows run inside a governed environment designed around controlled analysis.